UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-07 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.17 | -0.17 |
| Q1 2022 | 2022-05-05 | -0.18 | -0.18 |
| Q4 2021 | 2022-02-24 | -0.15 | -0.15 |
| Q3 2021 | 2021-11-09 | -0.12 | -0.12 |
| Q2 2021 | 2021-08-03 | -0.12 | -0.12 |
| Q1 2021 | 2021-05-12 | -0.11 | -0.11 |
| Q4 2020 | 2021-03-16 | -0.11 | -0.11 |
| Q3 2020 | 2020-11-03 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-04 | -0.17 | -0.17 |
| 2016-06-13 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-13 | Reiterated Rating | FBR & Co | Buy | |
| 2016-06-03 | Reiterated Rating | Robert W. Baird | Outperform | $7.00 |
| 2016-05-10 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-05-05 | Initiated Coverage | Cowen and Company | Outperform | |
| 2016-04-27 | Reiterated Rating | Cowen and Company | Outperform | |
| 2016-03-01 | Initiated Coverage | SunTrust | Buy | $3.00 |
| 2016-03-01 | Initiated Coverage | SunTrust Banks Inc. | Buy | $3.00 |
| 2016-02-29 | Reiterated Rating | Roth Capital | Buy | $5.00 |
| 2015-11-09 | Lower Price Target | Roth Capital | Buy | $6.00 to $5.00 |
| 2015-10-19 | Reiterated Rating | Robert W. Baird | Buy | $7.00 |
| 2015-10-19 | Reiterated Rating | Roth Capital | Buy | $5.00 |
| 2015-08-11 | Initiated Coverage | FBR & Co. | Outperform | $6.00 |
| 2015-08-10 | Lower Price Target | Roth Capital | Buy | $6.00 to $5.00 |
| 2015-07-25 | Reiterated Rating | Roth Capital | Buy | |
| 2015-07-06 | Reiterated Rating | Oppenheimer | Outperform | |
| 2015-07-06 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | |
| 2015-06-02 | Set Price Target | Roth Capital | Buy | $6.00 |
| 2015-06-01 | Boost Price Target | Robert W. Baird | Outperform | $5.00 to $7.00 |
| 2015-05-16 | Reiterated Rating | Stifel Nicolaus | Hold | |
| 2015-04-20 | Set Price Target | Robert W. Baird | Buy | $5.00 |
| 2015-01-22 | Boost Price Target | Oppenheimer | Outperform | $3.00 to $5.00 |
| 2015-01-21 | Lower Price Target | Roth Capital | Buy | $10.00 to $6.00 |
| 2014-10-16 | Reiterated Rating | Roth Capital | Positive | |
| 2014-05-09 | Lower Price Target | Oppenheimer | Outperform | $4.50 to $3.00 |
| 2014-03-24 | Lower Price Target | Roth Capital | $10.00 to $9.00 | |
| 2013-12-05 | Initiated Coverage | Wedbush | Outperform | $6.00 |
| 2013-11-21 | Lower Price Target | Mackie | Speculative Buy | C$1.80 to C$1.20 |
| 2013-11-07 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $8.00 to $3.00 |
| 2013-10-01 | Initiated Coverage | Robert W. Baird | Outperform | $7.00 |
| 2013-09-30 | Initiated Coverage | Chardan Capital | Buy | $6.00 |
| 2012-01-31 | Reiterated | Summer Street Research | Buy | $5 to $7 |
| 2011-10-06 | Initiated | Summer Street Research | Buy | $5 |
| 2011-09-22 | Initiated | MLV Capital | Buy | $8.50 |
| 2011-03-21 | Reiterated | Brean Murray | Buy | $4 to $5 |
| 2010-02-26 | Reiterated | Roth Capital | Buy | $5 to $4.50 |
| 2010-01-07 | Initiated | Roth Capital | Buy | $5 |
| 2009-11-24 | Initiated | ThinkEquity | Buy | |
| 2009-03-25 | Initiated | Merriman Curhan Ford | Buy |
| 2016-06-13 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-13 | Reiterated Rating | FBR & Co | Buy | |
| 2016-06-03 | Reiterated Rating | Robert W. Baird | Outperform | $7.00 |
| 2016-05-10 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-05-05 | Initiated Coverage | Cowen and Company | Outperform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CRIS 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Fattaey Ali Ph.D. President & COO | 0.37% (322140) | CRIS / |
| Rubin Marc | 0.28% (236596) | CRIS / GALT / TTNP / |
| GREENACRE MARTYN D | 0.26% (222945) | CRIS / NBS / |
| KAITIN KENNETH I | 0.25% (214607) | CRIS / |
| Dentzer James E Chief Financial Officer | 0.25% (212011) | CRIS / DRNA / |
| PASSERI DANIEL R CEO and Director | 0.25% (211798) | CRIS / |
| Martell Robert | 0.22% (185000) | CRIS / |
| Kunkel Lori Anne | 0.22% (185000) | CRIS / LOXO / |
| Tuck David Chief Medical Officer | 0.20% (169424) | CRIS / |
| TOBIN JAMES R | 0.17% (144921) | CRIS / GMED / OXFD / |
| GRAY MICHAEL COO and CFO | 0.12% (107304) | CRIS / |
| MCNAB JAMES R | 0.06% (50000) | CRIS / TTNP / |
| Pienta Kenneth | 0.03% (30000) | CRIS / |
| NOEL MARK Vice-President | 0.03% (27540) | CRIS / |
| BAYH SUSAN B | 0.03% (25000) | CRIS / DNDN / DYAX / EMMS / MRNA / |
UM